Glycoproteomics in neurodegenerative diseases |
| |
| Authors: | Hyejin Hwang Jianpeng Zhang Kathryn A. Chung James B. Leverenz Cyrus P. Zabetian Elaine R. Peskind Joseph Jankovic Zhen Su Aneeka M. Hancock Catherine Pan Thomas J. Montine Sheng Pan John Nutt Roger Albin Marla Gearing Richard P. Beyer Min Shi Jing Zhang |
| |
| Affiliation: | 1. Department of Pathology, University of Washington, Seattle, WA;2. Department of Neurology, Oregon Health and Science University, Portland, OR;3. Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, WA;4. Department of Neurology, University of Washington School of Medicine, Seattle, WA;5. Department of Neurology, Baylor College of Medicine, Houston, TX;6. Ann Arbor VAMC GRECC and Department of Neurology, University of Michigan, Ann Arbor, MI;7. Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA;8. Department of Environmental & Occupational Health Sciences, University of Washington School of Medicine, Seattle, WA |
| |
| Abstract: | Protein glycosylation regulates protein function and cellular distribution. Additionally, aberrant protein glycosylations have been recognized to play major roles in human disorders, including neurodegenerative diseases. Glycoproteomics, a branch of proteomics that catalogs and quantifies glycoproteins, provides a powerful means to systematically profile the glycopeptides or glycoproteins of a complex mixture that are highly enriched in body fluids, and therefore, carry great potential to be diagnostic and/or prognostic markers. Application of this mass spectrometry‐based technology to the study of neurodegenerative disorders (e.g., Alzheimer's disease and Parkinson's disease) is relatively new, and is expected to provide insight into the biochemical pathogenesis of neurodegeneration, as well as biomarker discovery. In this review, we have summarized the current understanding of glycoproteins in biology and neurodegenerative disease, and have discussed existing proteomic technologies that are utilized to characterize glycoproteins. Some of the ongoing studies, where glycoproteins isolated from cerebrospinal fluid and human brain are being characterized in Parkinson's disease at different stages versus controls, are presented, along with future applications of targeted validation of brain specific glycoproteins in body fluids. © 2009 Wiley Periodicals, Inc., Mass Spec Rev 29:79–125, 2010 |
| |
| Keywords: | glycoproteomics mass spectrometry Alzheimer's diseases Parkinson's disease biomarkers cerebrospinal fluids |
|
|
